Home

helps physicians and healthcare professionals

Erectile Dysfunction

helps physicians and healthcare professionals

Doctor123.org

helps physicians and healthcare professionals

Monoamine Oxidase Inhibitor Poisoning, Emergency Medicine


Basics


Description


  • Primarily for depression
  • Selegiline, a selective monoamine oxidase B inhibitor, is sometimes used to treat Parkinson disease, and also comes in a transdermal preparation.
  • Monoamine oxidase inhibitor (MAOI) pharmacologic actions:
    • Disruption of equilibrium between endogenous monoamine synthesis and degradation, resulting in:
      • Increased neural norepinephrine levels
      • Downregulation of several receptor types
    • Inhibition of irreversible (noncompetitive) enzyme
    • Inhibition of other B6-containing enzymes
  • MAO: Principal inactivator of neural bioactive amines:
    • MAO A:
      • Present in the gut and liver
      • Protects against dietary bioactive amines
    • MAO B:
      • Present in neuron terminals and platelets
      • Sympathomimetic amines: Types of bioactive amines

Etiology


  • MAOI overdose:
    • Toxicopharmacology poorly understood
    • MAO inhibitors: Amphetamine-like in structure:
      • Early: Indirect sympathomimetic effect
      • Late: Sympatholytic response (hypotension)
  • MAOI hypertensive crisis syndrome:
    • Results from impaired norepinephrine degradation and large norepinephrine release precipitated by an indirect- or mixed-acting sympathomimetic agent
    • Common precipitants: Tyramine, cocaine, amphetamines
  • Serotonin syndrome (SS):
    • Commonly results from exposure to combinations of agents that affect serotonin metabolism or action
    • Increases serotonin synthesis: Tryptophan
    • Increase serotonin release:
      • Indirect- and mixed-acting sympathomimetic agents and dopamine receptor agonists
    • Decrease serotonin reuptake:
      • Selective serotonin reuptake inhibitors
      • Tricyclic antidepressants
      • Newer antidepressants: Trazodone, nefazodone, venlafaxine
      • Phenylpiperidine opioids: Meperidine, dextromethorphan, tramadol, methadone, propoxyphene
    • Direct serotonin receptor agonists:
      • Buspirone, sumatriptan, lysergic acid diethylamide
    • Decrease serotonin breakdown:
      • MAOIs
    • Increases nonspecific serotonin activity:
      • Lithium

Diagnosis


Signs and Symptoms


  • MAOI overdose:
    • Delayed onset (6 " “12 hr)
    • Initial hypertension with headache
    • Hyperadrenergic activity:
      • Tachycardia
      • Hypertension
      • Mydriasis
      • Agitation
    • Neuromuscular excitation:
      • Nystagmus
      • Hyperreflexia
      • Tremor
      • Myoclonus
      • Rigidity
      • Seizures
    • Hyperthermia
    • Associated complications:
      • Rhabdomyolysis
      • Renal failure
      • Disseminated intravascular coagulation (DIC)
      • Acute respiratory distress syndrome (ARDS)
  • MAOI hypertensive crisis syndrome (MAOI interaction with drug or food):
    • Hypertension
    • Tachycardia or bradycardia
    • Hyperthermia
    • Headache, usually occipital
    • Altered mental status
    • Intracranial hemorrhage
    • Seizures
  • SS:
    • Increased neuromuscular activity
    • Increased deep tendon reflexes:
      • Lower extremity may be greater than upper
    • Tremor
    • Myoclonus
    • Rigidity (when severe)
    • Autonomic nervous system hyperactivity:
      • Hyperthermia
    • CNS:
      • Agitation
      • Hallucinations
      • Delirium
      • Coma
    • Diarrhea
    • SS vs. neuroleptic malignant syndrome (NMS):
      • Both present along a spectrum of severity (mild to severe)
      • Onset: Hours (SS) vs. days (NMS)
      • Gastrointestinal symptoms: May be present (SS) vs. absent (NMS)
      • Only drug/medication history may differentiate in many cases

History
  • Time of ingestion
  • Bottle available
  • Intentional or accidental
  • Coingestions

Physical Exam
  • Neuromuscular hyperactivity:
    • Myoclonus
    • Rigidity
    • Tremors
    • Hyperreflexia
  • Autonomic hyperactivity:
    • Tachycardia or bradycardia
    • Fever
    • Diaphoresis
  • Altered mental status:
    • Agitation, confusion, or excitement

Essential Workup


  • History of ingested substances
  • Rectal temperature monitoring as indicated
  • Blood pressure/cardiac monitoring

Diagnosis Tests & Interpretation


Lab
  • Urinalysis:
    • Blood
    • Myoglobin
  • Electrolytes, BUN/creatinine, glucose:
    • Hypoglycemia may contribute to altered mental status.
    • Acidosis may accompany severe toxicity.
    • Rhabdomyolysis may cause renal failure.
    • Hyperkalemia " ”life-threatening consequence of acute renal failure
  • Coagulation profile to monitor for potential DIC:
    • INR, prothrombin time, partial thromboplastin time, platelets
  • Creatinine kinase:
    • Markedly elevated in rhabdomyolysis
  • Urine toxicology screen:
    • May be positive for amphetamines, given the structural similarities between some MAOIs and amphetamines
  • Aspirin and acetaminophen levels if suicide attempt a possibility
  • Arterial blood gas

Imaging
  • Chest radiograph:
    • ARDS
  • Head CT if significant headache or altered mental status or focal neurologic signs:
    • Subarachnoid hemorrhage, intracerebral bleed

Diagnostic Procedures/Surgery
Lumbar puncture for: ‚  
  • Suspected meningitis (headache, altered mental status, hyperpyrexia)
  • Suspected subarachnoid hemorrhage and CT normal

Differential Diagnosis


  • Hyperthermia:
    • Infection
    • Hyperthyroidism
    • Heat stroke
    • Anatomic thalamic dysfunction
    • NMS
    • Malignant hyperthermia
    • Malignant catatonia
    • Ethanol or drug withdrawal
    • Anticholinergic toxicity
    • Sympathomimetic overdose
    • Cocaine-associated delirium/rhabdomyolysis
    • Salicylate toxicity
    • Theophylline toxicity
    • Nicotine toxicity
  • Hypertension:
    • Hypoglycemia
    • Carcinoid syndrome
    • Pheochromocytoma
    • Accelerated renovascular hypertension
    • Ethanol or drug withdrawal
    • Sympathomimetic toxicity

Treatment


Pre-Hospital


  • Patient may be uncooperative or violent.
  • Secure IV access.
  • Protect from self-induced trauma.

Initial Stabilization/Therapy


  • Airway, breathing, and circulation (ABCs)
  • IV access and fluid resuscitation if hypotensive
  • Oxygen
  • Cardiac monitor
  • Naloxone, thiamine, D50W (or Accu-Chek) if altered mental status

Ed Treatment/Procedures


  • Gastrointestinal decontamination:
    • In potential life-threatening ingestions gastric lavage may be carefully considered if within 1 hr of ingestion
    • Administer activated charcoal
  • Hyperthermia:
    • Benzodiazepines if agitated
    • Active cooling if temperature >40 ‚ °C:
      • Tepid water mist
      • Evaporate with fan
    • Paralysis:
      • Indicated if muscle rigidity and hyperactivity contributing to persistent hyperthermia
      • Nondepolarizing agent (e.g., vecuronium)
      • Avoid succinylcholine
      • Intubation; mechanical ventilation
    • Administer acetaminophen.
    • Apply cooling blankets.
  • Severe, malignant hypertension:
    • Nitroprusside (for MAOI overdose)
    • Calcium-channel blocker or phentolamine (for MAOI + food interaction)
    • Use short-acting IV agent that can be rapidly "turned off. " 
  • Hypotension:
    • Initially bolus with isotonic crystalloid solution
    • If no response, administer norepinephrine.
    • Dopamine may be ineffective
  • Dysrhythmias (premorbid sign in MAOI overdose):
    • Treatment based on dysrhythmia
  • Seizures:
    • Benzodiazepines
    • Barbiturates if benzodiazepines unsuccessful
    • Pyridoxine for refractory seizures
  • Rigidity:
    • Benzodiazepines
    • Paralysis with vecuronium, endotracheal intubation, and mechanical ventilation
  • ARDS:
    • Oxygen
    • Intubation and positive end-expiratory pressure as indicated
  • DIC:
    • Fresh-frozen plasma
    • Platelets
    • Whole-blood transfusions
  • Rhabdomyolysis:
    • IV isotonic crystalloid solution
    • Maintain hydration to ensure adequate urine output
  • Specific treatment for SS:
    • Mainstay: Supportive care, discontinuation of offending agents
    • Nonselective serotonin antagonist:
      • Cyproheptadine

Phentolaminecontraindicated in MAOI overdose (results in unopposed Ž ²-agonist) ‚  

Medication


  • Activated charcoal: 1 " “2 g/kg PO
  • Cyproheptadine: 4 " “8 mg PO/nasogastric tube q1 " “4h until therapeutic response; max. daily dose: 0.5 mg/kg (peds: 0.25 mg/kg/d; max. 12 mg/d; safety not established age <2 yr)
  • Dextrose: D50W 1 " “2 amp (50 " “100 mL or 25 " “50 g) (peds: D25W 2 " “4 mL/kg) IV push (IVP)
  • Diazepam: 5 " “10 mg (peds: 0.1 mg/kg slowly) increments IVP
  • Lorazepam: 1 " “2 mg increments IVP
  • Nitroprusside: 0.3 " “10 Ž Ό/kg/min IV
  • Norepinephrine: 2-4 Ž Ό/kg/min (peds: 0.05 " “0.1 Ž Ό/kg/min) IV
  • Phentolamine: 5 mg (peds: 0.05 " “0.2 mg/kg/dose) increments IVP
  • Sodium bicarbonate: Bolus 1 " “2 mEq/kg IVP; adult infusion: 3 amp (50 mEq per amp) sodium bicarbonate in 1,000 mL D5W at 2 " “3 mL/kg/h IV
  • Vecuronium: 0.1 mg/kg IVP

Follow-Up


Disposition


MAOI toxicity can occur in delayed fashion necessitating an extended observation period ‚  
Admission Criteria
  • All MAOI overdose patients require admission to a monitored unit for 24 hr.
  • ICU admission for seriously ill patients

Discharge Criteria
  • Resolved mild hypertensive syndrome or resolved mild serotonin syndrome may be discharged after several hours of ED observation.

Issues for Referral
Intentional overdoses should receive a psychiatry consult for suicide attempt. ‚  

Followup Recommendations


Following significant MAOI toxicity, medications need to be reassessed to prevent future crises. ‚  

Pearls and Pitfalls


  • Delayed onset of 6 " “12 hr prior to symptoms
  • Linezolid and methylene blue are MAOIs.
  • Phentolamine is contraindicated in MAOI overdose secondary to unopposed Ž ²-agonist.

Additional Reading


  • Boyer ‚  EW, Shannon ‚  M. The serotonin syndrome. New Engl J Med.  2005;352:1112 " “1120.
  • Brush ‚  DE, Bird ‚  SB, Boyer ‚  EW. Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. J Toxicol Clin Toxicol.  2004;42:191 " “195.
  • Gillman ‚  PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth.  2005;95:434 " “441.
  • Oates ‚  JA, Sjoerdsma ‚  A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology.  1960;10:1076 " “1078.
  • Ramsay ‚  RR, Dunford ‚  C, Gillman ‚  PK. Methylene blue and serotonin toxicity: Inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol.  2007;152:946 " “951.

See Also (Topic, Algorithm, Electronic Media Element)


Sympathomimetic Poisoning ‚  

Codes


ICD9


969.01 Poisoning by monoamine oxidase inhibitors ‚  

ICD10


  • T43.1X1A Poisoning by monoamine-oxidase-inhibitor antidepressants, accidental (unintentional), initial encounter
  • T43.1X2A Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter
  • T43.1X4A Poisoning by MAO inhib antidepressants, undetermined, init

SNOMED


  • 9291000 Poisoning by monoamine oxidase inhibitor (disorder)
  • 295889000 Overdose of monoamine oxidase inhibitor antidepressant drug (disorder)
  • 216548005 Accidental poisoning by monoamine oxidase inhibitors (disorder)
Copyright © 2016 - 2017
Doctor123.org | Disclaimer